Literature DB >> 16951495

Comparison of effects of smoking and smokeless tobacco "Maras powder" use on humoral immune system parameters.

Murat Aral1, Hasan Cetin Ekerbicer, Mustafa Celik, Pinar Ciragil, Mustafa Gul.   

Abstract

BACKGROUND: The aim of this study is to assess the impacts of "Maras powder" and cigarette smoking on the parameters of the humoral immune system.
MATERIAL AND METHODS: One hundred seventy seven subjects were included in the study. The IgA, IgG, IgM, C3 and C4 levels were detected via nephelometric method.
RESULTS: In 1.4% of the control group IgM levels were below normal where it was 10.8% and 18.6% in Maras powder group and in cigarette smoking group respectively. The IgM levels of both groups were significantly lower compared to the control group (P < .05). Nonetheless, the IgE levels of Maras powder group and smoking group were found to be remarkably higher compared to the control group (P < .01).
CONCLUSION: Effects of Maras powder on humoral immune response were found to be similar to that of smoking.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951495      PMCID: PMC1592592          DOI: 10.1155/MI/2006/85019

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


BACKGROUND

In Turkey a kind of smokeless tobacco called Maras powder has a lot of addicts in the city of Kahramanmaraş and its surroundings [1-3]. The leaves of Nicotina rustica L. are powdered, mixed, crushed with the ash obtained from the oak, walnut tree, or vine stick in the proportion of 1/2 or 1/3, and humidified a little before it is used. It is known that the ash blended during the preparation stage of Maras powder eases the absorption of nicotine from the mouth mucous membrane by making the medium alkaline. Maras powder is a kind of smokeless tobacco that is used by the addicts through buccal mucosa instead of cigarette or in order to give up smoking. On the other hand, it is more addictive than smoking. Its negative impacts on human health could not yet be understood fully. A similar kind of smokeless tobacco used in Sudan is known as Toombak. It is reported that Toombak use may play an important role in the etiology of oral squamosus cell carcinoma of the oral cavity and also may be associated with salivary gland cancers [4, 5]. Due to the fact that it is taken orally, it is reported that the cronic stimulation of the lenfoid tissues in oral mucous membrane may be related to the increased gingivitis, leukoplacis, and oral cancer incidence. Similarly, it is stated that it has a stronger potential of leading to addiction compared to cigarette smoking because of its higher nicotine concentration and prolonged mean usage time [6]. Most of the diseases related to smoking have been known in detail so far. More than 400 000 people die in the USA because of smoking and the direct expenditures for medical purposes regarding smoking-related morbidity exceed 50 million US dollars. The effect of smoking on the immune system and its parameters is not understood fully and the data about this is limited and somewhat contradictory. The studies up till now put forth that the immunotoxic and genotoxic impacts of cigarette arise from the particle phase more than the smoke-phase. The particle phase is composed of thousands of substances, but mainly nicotine. There are a lot of findings about the fact that nicotine is the major immunosuppressive in cigarette and/or smokeless tobacco. Nicotine causes the secretion of chatecolamines that have suppressive effects on immune system by inducing ACTH secretion [7]. It is crucial to clarify the relation between tobacco smoking and immune system in order to understand this biological process fully. The aim of this study was to determine the effects of Maras powder use and cigarette smoking on the parameters of humoral immune response.

MATERIALS AND METHODS

The study was conducted between January 2004 and June 2004 in Kahramanmaras Sutcu Imam University, Faculty of Medicine. All subjects included in the study population were healthy volunteers recruited from visitors. Informed consent was obtained from all the subjects participating in the study. The control group was composed of 33 women (41.1%) and 37 men (52.9%) with no history of smoking or Maras powder usage; the smokers group was composed of 31 women (42.2%) and 39 men (55.8%); and Maras powder group was composed of 17 women (45.9%) and 20 men (54.1%). The mean ages were 37.8 ± 12.5 SD (standard deviation) (min. 19–max. 73), 37.6 ± 12.0 SD (min. 20–max. 71), and 41.9 ± 10.2 SD in the control, smoking, and Maras powder groups, respectively. Mean ages and the sex distribution of the groups were similar (P > .05). Selection criteria of the individuals were as follows: cigarette smokers have been smoking a pack of cigarettes (twenty in number), Maras powder addicts have been using at least 2 packs of Maras powder (a pack is of 16 ± 3 g SD) for at least 5 years and nonpassive smoking for control and Maras powder users. The blood samples are collected from each subject by venipuncture of the cubital veins before labour and frozen at −20°C after aliquoting their sera until they are studied. Blood samples were analyzed for concentrations of the humoral immune system parameters (IgE, IgM, IgG, IgA, C3, and C4) using nephelometry (Dade Behring, Marburg GmbH, Germany). The normal values of humoral immune system parameters were accepted as 0.70–4.00 g/L for IgA, 7.0–16.0 g/L for IgG, 0.4–2.3 g/L for IgM, 0–100 IU/mL for IgE, 0.90–1.80 g/L for C3, and 0.10–0.40 g/L for C4. The values under these ranges were defined as “low” (there is no “low” value for IgE since its range starts from 0unIU/mL), and over these ranges as “high.” Data were expressed as mean values ± SD, median and range, or as number of subjects and percentages. Either nonparametric or parametric (if data was normally distributed) tests were used for statistical analyses. ANOVA and Kruskal-Wallis variance analysis (followed by post-hoc Mann-Whitney U test where needed) were used for comparison of numerical data. Chi-square tests were performed on categorical data. P values < .05 were considered statistically significant. Analyses were performed by using SPSS software, version 9.05 for Windows (SPSS Inc., Chicago, Ill).

RESULTS

Comparison of humoral immune system parameters in study groups were shown in Table 1. No statistically significant difference was detected among the parameters except for IgE (P > .05). IgE values of Maras powder and smoking groups were significantly higher than that of the control group (P < .05). Furthermore, the distribution of subjects according to ranges of humoral immune system parameters was compared (Table 2). For this purpose, data was classified as low, normal, and high for each parameter. The distribution of normal values was similar for each parameter except IgM and IgE. In control group 1.4% of the subjects had IgM values below normal where it was 18.6% and 10.8% in smoking and Maras powder groups, respectively (P < .05). After chi-square analysis, it was seen that IgE values above the normal had been similar in the smoking and Maras powder groups and significantly higher compared to the control group (P < 0.01).
Table 1

Comparison of humoral immune system parameters in study groups.

Control (n = 70)Smoking (n = 70)Maras powder (n = 37)P
Mean ± SDMin.–Med.–Max.Mean ± SDMin.–Med.–Max.Mean ± SDMin.–Med.–Max.

IgA (g/L)2.2 ± 0.90.6–2.0–5.71.9 ± 0.80.5–1.8–4.82.3 ± 0.90.3–2.3–4.5> .05
IgM (g/L)1.3 ± 0.50.4–1.3–3.21.3 ± 0.70.3–1.2–3.31.2 ± 0.40.5–1.2–2.3> .05
IgG (g/L)11.7 ± 2.77.9–11.3–20.812.9 ± 2.38.2–12.9–17.812.0 ± 3.76.9–11.8–31.3> .05
IgE (IU/mL)64.6 ± 43.918.0–54.0–236.0127.9 ± 76.218.6–113.5–290.0160.5 ± 85.9119.8–172.0–351.0< .01*
C3 (g/L)1.3 ± 0.30.7–1.3–1.91.4 ± 0.30.8–1.4–2.01.1 ± 0.30.4–0.9–1.8> .05
C4 (g/L)0.3 ± 0.00.1–0.2–0.60.2 ± 0.00.1–0.2–0.50.2 ± 0.10.1–0.2–0.8> .05

*The difference arose from control group.

Table 2

Distribution of the humoral immune system parameters with respect to low, normal, and high ranges in study groups.

LowNormalHighTotalP
n (%)n (%)n (%)n (%)

IgA* (g/L)< 0.700.70–4.00> 4.00
Control1 (1.4)67 (95.7)2 (2.9)70 (100.0)
Smoking7 (10.0)62 (88.6)1 (1.4)70 (100.0)
Maras powder3 (8.1)34 (91.9)37 (100.0)

IgM (g/L)< 0.40.4–2.3> 2.3
Control1 (1.4)68 (98.6)70 (100.0)< .05*
Smoking13 (18.6)57 (81.4)70 (100.0)
Maras powder4 (10.8)33 (89.2)37 (100.0)

IgG* (g/L)< 7.07.0–16.0> 16.0
Control1 (1.4)66 (94.3)3 (4.3)70 (100.0)
Smoking66 (94.3)4 (5.7)70 (100.0)
Maras powder1 (2.7)35 (94.6)1 (2.7)37 (100.0)

IgE (IU/mL)0–100.0> 100.0
Control53 (75.7)17 (24.3)70 (100.0)< .01*
Smoking25 (35.7)45 (64.3)70 (100.0)
Maras powder10 (27.0)27 (73.0)37 (100.0)

C3* (g/L)< 0.900.90–1.80> 1.80
Control62 (88.6)8 (11.4)70 (100.0)
Smoking65 (92.6)5 (7.1)70 (100.0)
Maras powder1 (2.7)32 (86.5)4 (10.8)37 (100.0)

C4* (g/L)< 0.100.10–0.40> 0.40
Control (none)66 (94.3)4 (5.7)70 (100.0)
Smoking67 (95.7)3 (4.3)70 (100.0)
Maras powder2 (5.4)33 (89.2)2 (5.4)37 (100.0)

*Statistical analysis could not be performed due to the limited number of cases.

**The difference arose from control group.

DISCUSSION

It was stated that using tobacco affects both the cellular and humoral immunity negatively in various ways. Nevertheless, the level of the negative effects could not yet be explained clearly. In a number of studies carried out for finding out the possible effects of cigarette smoke on lymphocytes, a leukocytosis accompanying the increase in all lymphocyte populations is mentioned. The relation between cigarette smoking and effects of cigarette smoke on in vitro lymphocyte functions is disputatious. Some authors reported that there had been significant reductions in the proliferative response of lymphocytes to T cell mitogens. On the other hand, some others reported that there had been no significant difference in terms of this response between smokers and nonsmokers. Besides, it was stated that these differences might have been influenced by age, sex, dosage, duration of exposure, and ethnic origin [8-15]. Goud et al [6] reported increases in lymphocyte proliferation and polyclonal IgM response caused by smokeless tobacco. However, Lindemann and Park [16] reported that water-soluble smokeless tobacco extract had anticytolytic and antiproliferative effects on peripheral lymphocytes. Possible causes for this disagreement could not be determined. In white subjects, it was shown that cigarette smoking was closely related to a series of immunological deteriorations accompanied by decreases in immunoglobulin levels, the number and the functions of NK (natural killer) cells, and the number of T cell subgroups [9, 11, 12, 14]. Moszczynski et al [17] had observed a decrease of CD4/CD8 ratio due to the decrease in the serum concentration of lysozyme and immunoglobulins and a decrease in the number of (CD 16+) NK cells particularly in the addicts who had smoked for more than 10 years and an increase in the number of (CD 8+) cytotoxic T lymphocytes. It was shown that smoking decreases serum levels of almost all types of immunoglobulins except IgE (IgE increases) [18-20]. There are also some articles that defend the idea that it has no particular effect on immunoglobulin levels [7]. In our study, rates of subjects with a serum IgM level below normal were significantly higher in smoking and Maras powder groups than in control group (P < .05). However, the differences of serum IgM levels between the 3 groups were not statistically significant. This may be interpreted as contradictory. When the data was studied carefully, it was seen that the IgM values below normal were very close to the lower limit. As for IgE levels, rates of subjects with values above normal were significantly higher in smoking and Maras powder groups than in control group (P < 0.01). Nearly all of the individuals (86.5%–95.7%) have levels of IgA, IgG, C3, and C4 within the normal limits. In some studies it was reported that alcaloid, nitrosamine, and nicotine contents distinguish between Nicotiana rustica L. and Nicotina tobacum L. alcaloid content of Maras powder (Nicotiana rustica L.) may be 6–10 times more than that of Nicotina tobacum L. [21]. It was reported that tobacco-specific nitrosamine content of Toombak was one hundred times more than that of other types of smokeless tobacco used in Sweden and USA, and Toombak use was described as the highest nonoccupational carcinogen exposure documented [4, 5]. Three times more urinary cotinine levels were found in Maras powder addicts than in smokers [22]. However, Lindemann et al reported that plasma nicotine levels were found to be similar in smokeless tobacco users and smokers [23]. Nevertheless, in our study, the effect of Maras powder on humoral immune response was found to be similar to that of smoking. As noted earlier in our study, many of the researchers stated that smoking affects the immune system and its parameters negatively at various levels. Nonetheless, the level of this negative effect could not be determined yet effectively and evidently. The information in literature does not show any coherence at all. We believe that further studies investigating the effects of different types of tobacco usage on humoral immune system parameters are needed.
  21 in total

1.  Effects of smokeless tobacco "Maras powder" use on respiratory functions.

Authors:  Mehmet Akif Buyukbese; Nurhan Koksal; Aytekin Guven; Ali Cetinkaya
Journal:  Tohoku J Exp Med       Date:  2004-11       Impact factor: 1.848

2.  Serum immunoglobulin levels throughout the life-span of healthy man.

Authors:  C E Buckley; F C Dorsey
Journal:  Ann Intern Med       Date:  1971-11       Impact factor: 25.391

Review 3.  Immune and inflammatory function in cigarette smokers.

Authors:  P G Holt
Journal:  Thorax       Date:  1987-04       Impact factor: 9.139

4.  Smoking and immunoglobulin levels.

Authors:  A Gulsvik; M K Fagerhoi
Journal:  Lancet       Date:  1979-02-24       Impact factor: 79.321

5.  Serum antibodies and immunoglobulins in smokers and nonsmokers.

Authors:  P Andersen; O F Pedersen; B Bach; G J Bonde
Journal:  Clin Exp Immunol       Date:  1982-02       Impact factor: 4.330

6.  Reversible alterations in immunoregulatory T cells in smoking. Analysis by monoclonal antibodies and flow cytometry.

Authors:  L G Miller; G Goldstein; M Murphy; L C Ginns
Journal:  Chest       Date:  1982-11       Impact factor: 9.410

7.  Immunoglobulin levels in smokers and non-smokers.

Authors:  J W Gerrard; D C Heiner; C G Ko; J Mink; A Meyers; J A Dosman
Journal:  Ann Allergy       Date:  1980-05

8.  Immunological findings in cigarette smokers.

Authors:  P Moszczyński; Z Zabiński; P Moszczyński; J Rutowski; S Słowiński; Z Tabarowski
Journal:  Toxicol Lett       Date:  2001-01-03       Impact factor: 4.372

Review 9.  Immunomodulatory effects of cigarette smoke.

Authors:  M L Sopori; W Kozak
Journal:  J Neuroimmunol       Date:  1998-03-15       Impact factor: 3.478

10.  The relationship of serum immunoglobulin E, allergy skin tests, and smoking to respiratory disorders.

Authors:  B Burrows; M Halonen; M D Lebowitz; R J Knudson; R A Barbee
Journal:  J Allergy Clin Immunol       Date:  1982-09       Impact factor: 10.793

View more
  5 in total

1.  Prevalence of oral Candida carriage and Candida species among cigarette and maras powder users.

Authors:  Hamit Sirri Keten; Derya Keten; Huseyin Ucer; Fatis Yildirim; Hakan Hakkoymaz; Oguz Isik
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Effects of smokeless tobacco (Maras powder) use on carotid intima media thickness.

Authors:  Mustafa Haki Sucakli; Fuat Ozkan; Mehmet Fatih Inci; Mustafa Celik; Hamit Sirri Keten; Orhan Bozoglan
Journal:  Med Sci Monit       Date:  2013-10-16

3.  Serum Immunoglobulins as Diagnostic Markers in Smokeless Tobacco Users for Prevention of Oral Potentially Malignant Disorders.

Authors:  Anjani Kumar Shukla; Tanya Khaitan; Prashant Gupta; Shantala Naik
Journal:  Asian Pac J Cancer Prev       Date:  2020-07-01

4.  Effects of smokeless tobacco "Maras powder" use on nitric oxide and cardiovascular risk parameters.

Authors:  Aytekin Guven; Fatma Tolun
Journal:  Int J Med Sci       Date:  2012-10-25       Impact factor: 3.738

5.  The effects of Maras powder use on patients with migraine.

Authors:  Yılmaz İnanç; Fatma Özlem Orhan; Yusuf İnanç
Journal:  Neuropsychiatr Dis Treat       Date:  2018-05-07       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.